Medtronic (MDT) May weekly 85 straddle priced into quarter results

Go back to Medtronic (MDT) May weekly 85 straddle priced into quarter results

RBC Capital Reiterates Sector Perform Rating on Medtronic, Inc. (MDT)

May 24, 2024 6:16 AM EDT

RBC Capital analyst Shagun Singh reiterated a Sector Perform rating and $92.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst comments "MDT delivered a beat (upside surprise of 1.7%/0.7% on sales/EPS, respectively), but FY25 guidance was in-line and FQ1 modestly below, sending... More

Medtronic, Inc. (MDT) PT Raised to $105 at Wells Fargo

May 24, 2024 5:20 AM EDT

Wells Fargo analyst Larry Biegelsen raised the price target on Medtronic, Inc. (NYSE: MDT) to $105.00 (from $102.00) while maintaining a Overweight rating.

The analyst comments "Strong FQ4 rev beat, but elevated opex drives muted EPS beat. MDT reported FQ4 2024 rev of $8.59B (+5.4% organic)... More

Medtronic, Inc. (MDT) PT Raised to $76 at UBS

May 24, 2024 4:59 AM EDT

UBS analyst Danielle Antalffy raised the price target on Medtronic, Inc. (NYSE: MDT) to $76.00 (from $75.00) while maintaining a Sell rating.

The analyst comments "Despite Outperformance, We Remain Skeptical of Sustainability of New Product Momentum; Commentary Suggests FY25 Consensus EPS Possibly... More

Stifel Reiterates Buy Rating on Medtronic, Inc. (MDT)

May 23, 2024 4:25 PM EDT

Stifel analyst Rick Wise reiterated a Buy rating and $100.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst comments "Notching a sixth consecutive mid-single-digit top-line revenue growth quarter (+5.4% organic), Medtronics 18 months of more-consistent performance positively suggest stable underlying business fundamentals. Now starting FY2025... More

BTIG Reiterates Neutral Rating on Medtronic, Inc. (MDT)

May 23, 2024 4:15 PM EDT

BTIG analyst Sean Lavin reiterated a Neutral rating on Medtronic, Inc. (NYSE: MDT).

The analyst comments "We maintain our Neutral rating following FY4Q24 results. MDT reported rev. of $8.589B (0.5% Y/Y, 5.4% organic) and adj. EPS of $1.46 (-7% Y/Y), above BTIG/Consensus ests. of $8.443B/$8.445B and adj. EPS of $1.46/$1.45 by ~1.7% and ~0.6% respectively. Segment performance was favorable in Neuroscience (3.6% vs. Cons), Medical-Surgical (1.1% vs. Cons), and Diabetes (+0.9% vs. Cons)... More